Amsterdam, The Netherlands and Uxbridge, UK, 27 June, 2019 – myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Immodulon, an immuno-oncology company, today announced a collaboration to develop an Expanded
Access Programme (EAP) for the unlicensed investigational drug IMM-101. Immodulon is progressing IMM-101 in a clinical development programme as a potential treatment in several cancer settings. The Expanded Access Programme will support the supply in Europe of IMM-101, an unlicensed medicine, when prescribed on a Named Patient basis for patients who have no other treatment options.
Steve Glass, COO of myTomorrows said, “I am delighted that myTomorrows is to strengthen the relationship with Immodulon. With our unique online platform, combined with our global capabilities of supporting expanded access and real-world data collection we aim to accelerate access to a medicine in development.”
Dr Jaap Kampinga, CEO of Immodulon commented, “We are progressing a clinical development programme investigating IMM-101 as a potential treatment in several cancer settings. With this programme ongoing, we also wish to put in place the appropriate infrastructure to ensure that cancer patients, who have no other treatment options, can access this medicine as efficiently as possible. As an expert in providing unlicensed medicines to patients through Expanded Access Programmes, myTomorrows is well placed to help us achieve this.”
Click here to download the press release